Joel Beatty

Stock Analyst at Baird

(4.62)
# 221
Out of 5,182 analysts
213
Total ratings
52.66%
Success rate
35.74%
Average return

Stocks Rated by Joel Beatty

e.l.f. Beauty
Apr 28, 2026
Maintains: Outperform
Price Target: $115$90
Current: $63.72
Upside: +41.24%
Denali Therapeutics
Apr 7, 2026
Maintains: Outperform
Price Target: $32$34
Current: $19.94
Upside: +70.51%
Immutep
Mar 13, 2026
Downgrades: Neutral
Price Target: $7$1
Current: $0.52
Upside: +90.66%
Dianthus Therapeutics
Mar 10, 2026
Maintains: Outperform
Price Target: $67$132
Current: $87.16
Upside: +51.45%
Contineum Therapeutics
Mar 6, 2026
Maintains: Outperform
Price Target: $14$20
Current: $13.00
Upside: +53.85%
Praxis Precision Medicines
Feb 20, 2026
Maintains: Outperform
Price Target: $275$433
Current: $330.99
Upside: +30.82%
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $72$47
Current: $23.99
Upside: +95.91%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $160$209
Current: $201.22
Upside: +3.87%
Amylyx Pharmaceuticals
Oct 16, 2025
Maintains: Outperform
Price Target: $10$19
Current: $16.88
Upside: +12.56%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10$7
Current: $4.44
Upside: +57.66%
Maintains: Outperform
Price Target: $4$6
Current: $2.89
Upside: +107.61%
Maintains: Neutral
Price Target: $7$9
Current: $36.61
Upside: -75.41%
Maintains: Outperform
Price Target: $28$31
Current: $22.30
Upside: +39.01%
Downgrades: Neutral
Price Target: $38$24
Current: $27.05
Upside: -11.28%
Upgrades: Outperform
Price Target: $680
Current: $783.74
Upside: -13.24%
Maintains: Outperform
Price Target: $70$66
Current: $69.22
Upside: -4.65%
Maintains: Outperform
Price Target: $160$162
Current: $187.40
Upside: -13.55%
Maintains: Outperform
Price Target: $38$41
Current: $33.73
Upside: +21.55%
Maintains: Outperform
Price Target: $28$32
Current: $29.27
Upside: +9.33%
Initiates: Outperform
Price Target: $75
Current: $90.24
Upside: -16.89%
Maintains: Neutral
Price Target: $72$65
Current: $53.81
Upside: +20.81%
Maintains: Outperform
Price Target: $540$240
Current: $0.24
Upside: +100,952.63%
Downgrades: Neutral
Price Target: $4.5
Current: $1.53
Upside: +194.12%
Maintains: Outperform
Price Target: $24$25
Current: $16.49
Upside: +51.61%
Maintains: Outperform
Price Target: $32$28
Current: $21.00
Upside: +33.33%
Initiates: Outperform
Price Target: $16
Current: $1.47
Upside: +988.44%
Maintains: Outperform
Price Target: $4$1.25
Current: $1.56
Upside: -19.87%
Initiates: Outperform
Price Target: $44
Current: $1.21
Upside: +3,536.36%
Maintains: Outperform
Price Target: $60$58
Current: $73.60
Upside: -21.20%
Maintains: Outperform
Price Target: $18$24
Current: $29.48
Upside: -18.59%
Downgrades: Underperform
Price Target: $18
Current: $8.30
Upside: +116.87%
Maintains: Outperform
Price Target: $9$6
Current: $1.72
Upside: +248.84%
Upgrades: Neutral
Price Target: $36$28
Current: $10.64
Upside: +163.16%
Downgrades: Neutral
Price Target: $170$175
Current: $308.51
Upside: -43.28%
Downgrades: Neutral
Price Target: $14
Current: $6.79
Upside: +106.19%
Downgrades: Neutral
Price Target: $108
Current: $20.98
Upside: +414.78%
Maintains: Buy
Price Target: $80$78
Current: $72.23
Upside: +7.99%
Maintains: Buy
Price Target: $140$100
Current: $20.39
Upside: +390.44%
Maintains: Buy
Price Target: $480$120
Current: $13.93
Upside: +761.45%
Maintains: Buy
Price Target: $480$450
Current: $4.21
Upside: +10,588.84%
Upgrades: Buy
Price Target: n/a
Current: $1.91
Upside: -
Maintains: Buy
Price Target: $19$15
Current: $8.07
Upside: +85.87%
Upgrades: Neutral
Price Target: $14$11
Current: $17.65
Upside: -40.51%
Maintains: Buy
Price Target: $15$19
Current: $9.07
Upside: +109.48%